DiscoverAI in Medicine - curated summaries making complex issues easy to understand
AI in Medicine - curated summaries making complex issues easy to understand

AI in Medicine - curated summaries making complex issues easy to understand

Author: Mike Rawson

Subscribed: 13Played: 222
Share

Description

AI in Medicine - Smart Summaries is a daily podcast for clinicians, health-system leaders and medtech, pharma and digital-health teams.

Each episode unpacks one important public document on artificial intelligence in healthcare, such as FDA, EMA, MHRA, WHO or NHS guidance, OECD and World Economic Forum reports, or an open-access peer-reviewed review, in a clear 15 to 20 minute conversation.

Topics include clinical AI and decision support, medical imaging and radiology AI, large language models (LLMs) and generative AI in clinical practice, AI-enabled medical devices and their regulation, the EU AI Act, drug discovery and clinical trials, digital health and wearables, health-system adoption, patient safety, bias and liability.

The source of every episode is linked in the show notes, and full transcripts are at ai-in-medicine-podcast.vercel.app. The hosts' voices are AI-generated. For information only, not medical advice.
183 Episodes
Reverse
In this episode, we unpack a 2026 scoping review examining conversational AI agents used for psychological support in cancer care. We explore the massive gap between testing AI for user experience and actually equipping it to handle clinical distress. Listeners will learn why fewer than a fifth of these projects formally evaluate safety, and what that means for developers and oncology teams building psycho-oncology tools. Key points An umbrella review cited in the document found pooled prevalence estimates of 33.16% for depression and 30.55% for anxiety among patients with cancer, underscoring the need for scalable support.Out of 24 reports mapped, 70.8% evaluated acceptability or user experience, but only 16.7% explicitly reported evaluating safety or adverse events.While 100% of the 23 mapped projects included information or education functions, only 33.3% of the reports described crisis escalation or referral protocols.The implementation of structured psychological interventions dropped to just 21.7% when looking exclusively at systems that were actually delivered to patients, rather than simulated or planned.User-facing AI identity disclosure was notably low, reported in just 12.5% of the included reports, highlighting major gaps in transparency. Source: Mapping Technologies, Support Functions, Evaluation Outcomes, and Safety Governance Related to Conversational AI Agents for Psychological Support of Patients With Cancer: Scoping Review - Journal of medical Internet research, 2026 (CC BY) This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source. Authors: Zhiying Shen, Shuangjiao Shi, Lian Mao, Chengyuan Li, Jianfei Xie · DOI: 10.2196/105599 Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/who-catches-cancer-patients-in-crisis-ai-chatbots-distress-and-the-saf-df8b00
We unpack the public FDA 510(k) summary for eMurmur Heart AI (2.2), a software system designed to analyze patient heart sounds and detect abnormal murmurs. We break down the clinical performance data, the software's transition to supporting multiple digital stethoscopes, and how the company's Predetermined Change Control Plan allows for future hardware updates. Key points eMurmur Heart AI (2.2) is cleared as a decision support system for evaluating recorded patient heart sounds in pediatric and adult patients.The software identifies S1 and S2 heart sounds, detects abnormal murmurs, and introduces a new feature to determine the average loudness of individual heart sound components.Performance testing on previously unseen data showed the device achieved 90.0% sensitivity, 90.0% specificity, and 90.0% accuracy in detecting abnormal murmurs.The ground truth for the validation dataset was established by three board-certified cardiologists based on a majority consensus.The device utilizes an accessory called the eMurmur Transformer to ensure consistent analysis across multiple supported digital stethoscope models.An authorized Predetermined Change Control Plan allows the company to add new stethoscope models without a new 510(k) submission, provided they meet specific statistical non-inferiority targets. Source: FDA 510(k) summary K252284: eMurmur Heart AI (Csd Labs) - U.S. Food and Drug Administration, 2025 This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source. Company: Csd Labs · Product: eMurmur Heart AI · FDA 510(k) K252284 Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-csd-labs-emurmur-heart-ai-90-0-accuracy-in-automated-fbe145
AI scribes are rapidly entering hospitals to save clinicians from documentation burnout, but who is legally responsible when the software hallucinates a diagnosis or drops a critical negation? This episode unpacks a PLOS Digital Health analysis of 74 official regulatory documents governing AI scribes. We explore the drafting fiction that shifts liability onto doctors, the biometric privacy risks of voice data, and why hospital leaders must rethink protected review time before deploying ambient tools. Key points Official guidance treats AI-generated notes as provisional drafts that require clinician authentication, a concept the study calls the drafting fiction.An analysis of 74 official documents reveals that while vendor contracts address broad product risks, the liability for individual note errors falls entirely on the verifying clinician.Medical device classification can shift after deployment depending on whether the AI performs simple transcription or interpretative summarisation.Privacy concerns extend far beyond secure storage, as spoken consultations contain biometric voiceprint data that can be virtually impossible to de-identify.Current guidelines fail to allocate protected time for clinicians to review AI notes, monitor for accent biases, or maintain manual documentation pathways for patients who refuse consent. Source: Regulating the drafting fiction: A qualitative content analysis of official guidance and regulator documents on AI scribe adoption and use in healthcare - PLOS Digital Health, 2026 This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source. Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/who-gets-sued-when-an-ai-scribe-hallucinates-the-hidden-liability-of-a-b2bc6f
This episode unpacks the FDA 510(k) clearance summary for Ever Fortune.AI's EFAI ETTXR system, an AI tool designed to flag malpositioned endotracheal tubes on adult chest X-rays. We break down the clinical testing data, the algorithm's specific measurement thresholds, and crucial limitations regarding esophageal intubation and double lumen tubes. Key points The EFAI ETTXR is a radiological triage software that analyzes adult chest X-rays to flag suspected vertically malpositioned endotracheal tubes in relation to the carina.In a retrospective, multisite clinical validation study of 940 studies, the device demonstrated a sensitivity of 0.890 and a specificity of 0.935.The software triggers a flag if the endotracheal tube tip is assessed as more than 7 cm above the carina, less than 3 cm above the carina, or below the carina.The device provides a passive notification via a text-based JSON file to prioritize worklists, but does not highlight or mark the original image.Crucial limitations include the inability to detect esophageal intubation, a lack of awareness of patient positioning, and the potential to trigger false alerts for properly positioned double lumen tubes. Source: FDA 510(k) summary K242821: EFAI Chestsuite XR Malpositioned ETT Assessment System (ETT-XR-100) (Ever Fortune.AI) - U.S. Food and Drug Administration, 2025 This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source. Company: Ever Fortune.AI · Product: EFAI Chestsuite XR Malpositioned ETT Assessment System (ETT-XR-100) · FDA 510(k) K242821 Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-ever-fortune-ai-ett-xr-100-ai-triage-for-misplaced-e-396e7d
We unpack the FDA 510(k) summary for Us2.ca, an AI software device by Us2.ai designed to detect cardiac amyloidosis from echocardiograms. We break down the clinical testing data, demographic performance differences, and key limitations hospital buyers need to know. Key points Us2.ca is cleared via the FDA 510(k) pathway as substantially equivalent to the predicate device, EchoGo Cardiac Amyloidosis 1.0.The software is indicated for adult patients with a specific left ventricular wall thickness of ≥ 12mm.In retrospective testing of 1,647 patients, the device produced a confident prediction for 1434 patients, yielding an 87.1% success rate.Performance on the confident predictions showed an overall sensitivity of 86.9% and specificity of 87.4%.The summary outlines strict limitations: it does not provide a diagnosis, does not highlight regions of interest on the image, and was only externally validated on GE and Philips ultrasound systems. Source: FDA 510(k) summary K250151: Us2.ca (Eko.Ai Pte) - U.S. Food and Drug Administration, 2025 This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source. Company: Eko.Ai Pte · Product: Us2.ca · FDA 510(k) K250151 Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-us2-ai-us2-ca-ai-detection-for-cardiac-amyloidosis-67a2d8
loading
Comments